ATE331523T1 - Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion - Google Patents
Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktionInfo
- Publication number
- ATE331523T1 ATE331523T1 AT03745196T AT03745196T ATE331523T1 AT E331523 T1 ATE331523 T1 AT E331523T1 AT 03745196 T AT03745196 T AT 03745196T AT 03745196 T AT03745196 T AT 03745196T AT E331523 T1 ATE331523 T1 AT E331523T1
- Authority
- AT
- Austria
- Prior art keywords
- cognitive function
- statin therapy
- statin
- maintaining cognitive
- galantamine
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 4
- 206010012289 Dementia Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229960003980 galantamine Drugs 0.000 abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36928502P | 2002-04-02 | 2002-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE331523T1 true ATE331523T1 (de) | 2006-07-15 |
Family
ID=28675573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03745196T ATE331523T1 (de) | 2002-04-02 | 2003-03-28 | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1492539B1 (de) |
| JP (1) | JP2005525391A (de) |
| KR (1) | KR100986194B1 (de) |
| CN (1) | CN100528164C (de) |
| AT (1) | ATE331523T1 (de) |
| AU (1) | AU2003226753B2 (de) |
| BR (1) | BR0308293A (de) |
| CA (1) | CA2480275C (de) |
| CY (1) | CY1105545T1 (de) |
| DE (1) | DE60306503T2 (de) |
| DK (1) | DK1492539T3 (de) |
| EA (1) | EA013069B1 (de) |
| ES (1) | ES2268393T3 (de) |
| IL (2) | IL164317A0 (de) |
| MX (1) | MXPA04009535A (de) |
| NO (1) | NO20044698L (de) |
| NZ (1) | NZ536111A (de) |
| PL (1) | PL211160B1 (de) |
| PT (1) | PT1492539E (de) |
| UA (1) | UA79605C2 (de) |
| WO (1) | WO2003082298A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603548A4 (de) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen |
| EP1737539A1 (de) * | 2004-04-14 | 2007-01-03 | Warner-Lambert Company LLC | Therapeutische kombination zur behandlung von alzheimer-krankheit |
| EP1604686A1 (de) * | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Verwendung von Phenserine und einem HMG CoA reduktase Hemmer zur Verzögerung der Alzheimer Krankheit |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| US20160303146A1 (en) * | 2013-12-13 | 2016-10-20 | David A. TABACZYNSKI | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
-
2003
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko not_active Expired - Fee Related
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en not_active Ceased
- 2003-03-28 EP EP03745196A patent/EP1492539B1/de not_active Expired - Lifetime
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
-
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
-
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL211160B1 (pl) | 2012-04-30 |
| CN100528164C (zh) | 2009-08-19 |
| PT1492539E (pt) | 2006-11-30 |
| KR100986194B1 (ko) | 2010-10-07 |
| DE60306503T2 (de) | 2007-06-21 |
| DK1492539T3 (da) | 2006-10-30 |
| PL371551A1 (en) | 2005-06-27 |
| CY1105545T1 (el) | 2010-07-28 |
| IL164317A0 (en) | 2005-12-18 |
| AU2003226753B2 (en) | 2007-06-28 |
| AU2003226753A1 (en) | 2003-10-13 |
| NZ536111A (en) | 2006-03-31 |
| NO20044698L (no) | 2004-10-29 |
| EA200401295A1 (ru) | 2005-02-24 |
| DE60306503D1 (de) | 2006-08-10 |
| HK1079688A1 (zh) | 2006-04-13 |
| JP2005525391A (ja) | 2005-08-25 |
| CN1642555A (zh) | 2005-07-20 |
| MXPA04009535A (es) | 2005-01-25 |
| EP1492539B1 (de) | 2006-06-28 |
| UA79605C2 (en) | 2007-07-10 |
| EP1492539A1 (de) | 2005-01-05 |
| ES2268393T3 (es) | 2007-03-16 |
| BR0308293A (pt) | 2004-12-28 |
| KR20040096608A (ko) | 2004-11-16 |
| IL164317A (en) | 2010-04-29 |
| EA013069B1 (ru) | 2010-02-26 |
| CA2480275C (en) | 2011-08-16 |
| WO2003082298A1 (en) | 2003-10-09 |
| CA2480275A1 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| DK1289517T3 (da) | Farmaceutiske sammensætninger indeholdende cannabidiolderivater | |
| BG106095A (bg) | Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици | |
| MXPA05003253A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos. | |
| NO952906D0 (no) | Farmasöytisk formulering for behandling av nikotinavhengighet | |
| DE69706566D1 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
| HUP0100539A2 (hu) | D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására | |
| ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| BR0211970A (pt) | Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| BG105342A (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| TW200633694A (en) | Composition and method for treating asthma | |
| ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
| EP1603595A4 (de) | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
| ATE337790T1 (de) | Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen | |
| WO2004073627A3 (en) | Novel therapeutic method and compositions for topical administration | |
| ATE334675T1 (de) | Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1492539 Country of ref document: EP |